Health Industry Washington Watch : Washington DC Healthcare Industry Law Firm : Reed Smith : Health Industry Washington Watch : Regulations, Medicare/Medicaid, Governmental Organizations
New York, London, Hong Kong, Chicago, Washington, D.C., Beijing, Paris, Los Angeles, San Francisco, Philadelphia, Pittsburgh, Oakland, Munich, Abu Dhabi, Princeton, Northern Virginia, Wilmington, Silicon Valley, Dubai, Century City, Richmond, GreecePublished by
ReedSmith
Updates by Reed Smith on U.S. legislative and regulatory developments affecting the life sciences and health care industry sector
Search This Site
Enter keywords:
Subscribe
Add this blog to your feeds or put your e-mail in the box below and hit GO to subscribe by e-mail.
Reed Smith Sites
- Ship Law Log
- Taxing Tech
- Private Funds Law Update
- Financial Regulatory Report
- Developing Concerns
- The Swap Report
- Global Regulatory Enforcement Law Blog
- ReACTS Blog
- China Media & Entertainment Law Report
- Lending Law Report
- Real Estate Legal Update
- Adlaw by Request
- Legal Bytes
- Employment Law Watch
- Environmental Law Resource
- Life Sciences Legal Update
- Life Sciences Health Industry Group
- Reed Smith
Recent Updates
- CMS Releases Long-Awaited Proposed Rule to Implement ACA Medicaid Manufacturer Rebate and Pharmacy Reimbursement Provisions
- Overview and Analysis of the Proposed Federal Sunshine Regulations
- New Postings on the Reed Smith Health Industry Washington Watch Blog
- Fall 2011 Regulatory Agenda (Belatedly) Released
- CMS Finalizes Rules on Payments to Retiree Prescription Drug Plan Sponsors
- CMS Proposes Changes to Medicaid DSH Rules
- HHS Rule on Adoption of Standards for Health Care Electronic Funds Transfers
- HHS Revises Rules Regarding Coverage of Contraceptive Services for Certain Religious Groups Offering Insurance
- CMS Establishes Procedures for Claims Against DMEPOS Surety Bonds
- CMS Releases Additional Draft ACA Medicaid Drug Pricing/FUL Files
- FDA Seeks Comments on Prescription Drug Promotion Survey
- FDA Completes Work on Three Drug User Fee Programs
Key Regulatory Sites